Literature DB >> 10769067

Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1.

S M Cleveland1, T D Jones, N J Dimmock.   

Abstract

The possibility that epitopes from the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 (HIV-1) are exposed the surface of the virion has long been contentious. Resolution of this has been hampered by the absence of any neutralizing monoclonal antibodies, but we have recently epitope-purified a neutralizing polyclonal IgG specific for one of the putative gp41 tail epitopes, (746)ERDRD(750). This was obtained from mice immunized parenterally with a plant virus chimera expressing residues 731-752 from the gp41 tail. The ERDRD epitope is highly conformational and is conserved in 81% of B clade viruses. Here, it is shown that this polyclonal ERDRD-specific IgG is highly potent, with an affinity of 2.2x10(8) M(-1), and a neutralization rate constant (-K(neut)) of 7.8x10(4) M(-1) s(-1) that exceeds that of nearly all other known HIV-1-neutralizing antibodies. ERDRD-specific IgG gave 50% neutralization at 0.1-0.2 microg/ml and 90% neutralization at approximately 3 microg/ml. It also neutralized virus that was already attached to target cells, and this and other data suggest that it neutralized by inhibiting a virion event that precedes the fusion-entry process. Consistent with this conclusion was the finding that neutralizing amounts of ERDRD-specific IgG did not inhibit the attachment of free virus to target cells. ERDRD-specific IgG was also cross-reactive and neutralized all but one of six B clade T cell line-adapted strains tested.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10769067     DOI: 10.1099/0022-1317-81-5-1251

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event.

Authors:  M J Edwards; N J Dimmock
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties.

Authors:  Rasmus Lundquist; Leif Kofoed Nielsen; Ali Jafarshad; Daw Soesoe; Lars Harder Christensen; Pierre Druilhe; Morten Hanefeld Dziegiel
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

3.  Interaction between a 54-kilodalton mammalian cell surface protein and cowpea mosaic virus.

Authors:  Kristopher J Koudelka; Chris S Rae; Maria J Gonzalez; Marianne Manchester
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

4.  Single-chain antibody fragment specific for Plasmodium vivax Duffy binding protein.

Authors:  So-Hee Kim; Seung-Young Hwang; Yong-Seok Lee; In-Hak Choi; Sae-Gwang Park; Weon-Gyu Kho
Journal:  Clin Vaccine Immunol       Date:  2007-04-25

5.  Evidence for mixed membrane topology of the newcastle disease virus fusion protein.

Authors:  Lori W McGinnes; Julie N Reitter; Kathy Gravel; Trudy G Morrison
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

6.  The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, and D may exist in two conformations: an analysis of sequence, structure, and function.

Authors:  Mark J Hollier; Nigel J Dimmock
Journal:  Virology       Date:  2005-07-05       Impact factor: 3.616

Review 7.  C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic.

Authors:  Jonathan D Steckbeck; Anne-Sophie Kuhlmann; Ronald C Montelaro
Journal:  J Gen Virol       Date:  2012-10-17       Impact factor: 3.891

8.  Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein.

Authors:  Joshua M Costin; Joshua M Rausch; Robert F Garry; William C Wimley
Journal:  Virol J       Date:  2007-11-20       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.